MedTrace Logo

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

NCT05039177 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2026-03-25

No results posted yet for this study

Summary

* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies.
* To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies.
* To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies.
* To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.

Conditions

Interventions

DRUG

ERAS-007

Administered orally

DRUG

Encorafenib

Administered orally

DRUG

Cetuximab

Administered via intravenous infusion

DRUG

Palbociclib

Administered orally

Sponsors & Collaborators

  • Erasca, Inc.

    lead INDUSTRY

Principal Investigators

  • Joyce Antal · Clinical Development

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2025-08-15
Completion
2026-01-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05039177 on ClinicalTrials.gov